3.39

6.87% -0.25

Pre-market: 3.40 0.010 +0.29%

23 Andme Holding Co (ME)

Overview News Price History Option Chain Financials Discussions Forecast

23 Andme Holding Co stock is traded at $3.39, with a volume of 192.28K. It is down -6.87% in the last 24 hours and up +1.19% over the past month. 23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.

Previous Close:

$3.64

Open:

$3.7

24h Volume:

192.28K

Relative Volume:

0.59

Market Cap:

$88.54M

Revenue:

$247.99M

Net Income/Loss:

$-521.97M

P/E Ratio:

-3.0541

EPS:

-1.11

Net Cash Flow:

$-194.28M

1W Performance:

-14.39%

1M Performance:

+1.19%

6M Performance:

-64.90%

1Y Performance:

-76.06%

1-Day Range:

$3.37

$3.79

1-Week Range:

$3.37

$4.18

52-Week Range:

$2.655

$16.52

23 Andme Holding Co Stock (ME) Company Profile

Name

23 Andme Holding Co

Sector

Healthcare (1191)

Industry

Diagnostics & Research (58)

Phone

(650) 938-6300

Address

223 N. MATHILDA AVE., SUNNYVALE

Employee

582

Twitter

Next Earnings Date

2024-12-12

Latest SEC Filings

ME's Discussions on Twitter

Compare ME with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ME 23 Andme Holding Co	3.39	88.54M	247.99M	-521.97M	-194.28M	-1.11
TMO Thermo Fisher Scientific Inc	556.99	213.05B	42.37B	6.14B	7.78B	15.95
DHR Danaher Corp	237.62	171.63B	23.74B	3.89B	4.98B	5.24
A Agilent Technologies Inc	143.43	40.54B	6.51B	1.29B	1.37B	4.42
IQV Iqvia Holdings Inc	197.96	35.93B	15.32B	1.41B	1.96B	7.62
IDXX Idexx Laboratories Inc	418.63	34.28B	3.84B	866.24M	792.60M	10.37

23 Andme Holding Co Stock (ME) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-29-22	Initiated	Berenberg	Buy
Sep-22-22	Initiated	Cowen	Outperform
Nov-15-21	Downgrade	Citigroup	Buy → Neutral
Aug-17-21	Initiated	Credit Suisse	Outperform
Jul-12-21	Initiated	Citigroup	Buy

23 Andme Holding Co Stock (ME) Latest News

Jan 12, 2025

Jane Street Group LLC Sells 1,561,678 Shares of 23andMe Holding Co. (NASDAQ:ME) - MarketBeat

Jan 12, 2025

Jan 08, 2025

23andMe Launches Discover23 to Help Accelerate Large-Scale Genetics Research For Biopharma Collaborators, Powered By Lifebit's Trusted Technology - The Manila Times

Jan 08, 2025

23andMe Launches Discover23 to Help Accelerate Large-Scale - GlobeNewswire

Jan 08, 2025

23andMe Launches Discover23 Platform with Massive 4.7B Genetic Data Points for Medical Research - StockTitan

Jan 08, 2025

Jan 07, 2025

23andMe Holding Co. (NASDAQ:ME) Short Interest Down 16.6% in November - MarketBeat

Dec 14, 2024

Dec 05, 2024

23andMe Stock Price Prediction: 2024, 2025, 2030 - Benzinga

Dec 05, 2024

Dec 04, 2024

23Andme Holding Co earnings missed by $2.16, revenue topped estimates - Investing.com Nigeria

Dec 04, 2024

Dec 03, 2024

US Penny Stocks: 3 Picks With Market Caps Under $200M - Simply Wall St

Dec 03, 2024

Dec 02, 2024

Wojcicki ‘Committed’ to Taking 23andMe Private as Board Quits - MSN

Dec 02, 2024

Nov 30, 2024

23andMe (NASDAQ:ME) Trading 13.1% HigherHere's Why - MarketBeat

Nov 30, 2024

Nov 27, 2024

23andMe CEO Anne Wojcicki responds to critics, shares plan for company's future: "Essential for us to restructure" - CBS News

Nov 27, 2024

23andMe’s stock falls after company says there’s substantial doubt it can stay in business - MSN

Nov 27, 2024

Nov 22, 2024

23andMe shares dip as Q2 loss widens despite revenue beat By Investing.com - Investing.com Nigeria

Nov 22, 2024

Nov 21, 2024

Do Redditors Think That 23andMe Holding Co. (ME) Has a Big Upside Potential? - Insider Monkey

Nov 21, 2024

Nov 20, 2024

Struggling 23andMe Is Exploring Splitting the DNA Company in Two - MSN

Nov 20, 2024

23andMe inks research deal with Mirador Therapeutics By Investing.com - Investing.com Canada

Nov 20, 2024

23andMe to slash 40% of its workforce, end therapeutics program to cut costs - MSN

Nov 20, 2024

23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador's Precision Medicines for Immunology & Inflammation - The Manila Times

Nov 20, 2024

23andMe inks research deal with Mirador Therapeutics - Investing.com India

Nov 20, 2024

23andMe and Mirador Therapeutics Enter Into Strategic - GlobeNewswire

Nov 20, 2024

23andMe Partners with Mirador in Major Drug Development Collaboration | ME Stock News - StockTitan

Nov 20, 2024

Nov 14, 2024